FDA pauses Regenxbio trial again after spine masses found in 5 patients

The FDA has again paused Regenxbios RGX-121 gene therapy trial for Hunter syndrome after small, asymptomatic masses were found on the spines of five patients. Regenxbio does not expect to resubmit its biologics license application for the therapy in the near term. The spine findings, either a small nodule or cystic mass, surfaced through an […] The post FDA pauses Regenxbio trial again after spine masses found in 5 patients appeared first on Becker's Hospital Review | Healthcare News...